Benzinga | Nov 5, 2020 08:14AM EST

Biocept Awarded Broad Japanese Patent For Use Of Binding Entities In Combination With Any Solid Surface To Capture And Detect Any Target Of Interest, Including CTCs, From Any Sample Type

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded Japanese Patent No. 6771010 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers devices for the detection of any target of interest, including circulating tumor cells (CTCs) that are shed into the blood stream by solid tumors where a binding entity, including antibodies or mixture of binding entities, or antibodies and any solid surface are used for target capture, detection, and analysis. This patent includes any biological sample type of interest and includes the use of single entities or cocktails of binding entities.